A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease

This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplantation 2005-02, Vol.79 (3), p.372-374
Hauptverfasser: HORI, Akiko, KANDA, Yoshinobu, KOJIMA, Rie, HAMAKI, Tamae, SAKIYAMA, Michiyo, KAMI, Masahiro, MAKIMOTO, Atsushi, TANOSAKI, Ryuji, TAKAUE, Yoichi, HIRAI, Hisamaru, GOYAMA, Susumu, ONISHI, Yasushi, KOMENO, Yukiko, MITANI, Kinuko, KISHI, Yukiko, OGAWA, Seishi, IMATAKI, Osamu, CHIBA, Shigeru
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 374
container_issue 3
container_start_page 372
container_title Transplantation
container_volume 79
creator HORI, Akiko
KANDA, Yoshinobu
KOJIMA, Rie
HAMAKI, Tamae
SAKIYAMA, Michiyo
KAMI, Masahiro
MAKIMOTO, Atsushi
TANOSAKI, Ryuji
TAKAUE, Yoichi
HIRAI, Hisamaru
GOYAMA, Susumu
ONISHI, Yasushi
KOMENO, Yukiko
MITANI, Kinuko
KISHI, Yukiko
OGAWA, Seishi
IMATAKI, Osamu
CHIBA, Shigeru
description This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum dose was administered over 8 weeks. There were no severe adverse events caused by pravastatin. A clinical response was observed in the skin score in two patients, mouth score in five patients, eye score in two patients, liver score in three patients, platelet count score in one patient, and weight loss in two patients. The overall response rate was 28%. Immunophenotypic analyses showed that T-helper (Th)1 cells were dominant in all but one patient before treatment and that the Th1/Th2 ratio tended to be lower in the responders than in the nonresponders. A randomized controlled trial is warranted to evaluate the efficacy of pravastatin against chronic GVHD.
doi_str_mv 10.1097/01.tp.0000151001.64189.1d
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19280214</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19280214</sourcerecordid><originalsourceid>FETCH-LOGICAL-c522t-adb72671d9796ad7a9d5072b40079846201054a317e6d58cf45027060e4e2be23</originalsourceid><addsrcrecordid>eNpFkc2O1DAQhC0EYoeFV0DmALeEbseO4-Nq-ZVWgsNytnqcDhOUSQbbGWnegMfGuzvS9MEtWV_Zqioh3iHUCM5-BKzzoYYyaLAcdauxczX2z8QGTaOrFjp4LjYAGitsGnslXqX0p_CmsfaluELTOmet3oh_N_IQl3TgkMcjyxxHmmReJB9pWimXmx3LRAPnk6S5lzwMY6BwkstQhHSklCmPsxyW-IjmyJT3POcHIPIQKeQlnmTYxWUeg_wdacjVkWNaU7VbUpb9mJgSvxYvBpoSvznva_Hry-f722_V3Y-v329v7qpglMoV9VurWou9s66l3pLrDVi11QDWdbpVgGA0NWi57U0XBm1AWWiBNastq-ZafHh6t9j-u3LKfj-mwNNEMy9r8uhUBwp1Ad0TGEo-qVjxhzjuKZ48gn-owQP6-5_-UoN_rMHjp6J9e_5k3e65vyjPuRfg_RmgFGgqMc1hTBeuNapguvkPjL6Svw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19280214</pqid></control><display><type>article</type><title>A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>HORI, Akiko ; KANDA, Yoshinobu ; KOJIMA, Rie ; HAMAKI, Tamae ; SAKIYAMA, Michiyo ; KAMI, Masahiro ; MAKIMOTO, Atsushi ; TANOSAKI, Ryuji ; TAKAUE, Yoichi ; HIRAI, Hisamaru ; GOYAMA, Susumu ; ONISHI, Yasushi ; KOMENO, Yukiko ; MITANI, Kinuko ; KISHI, Yukiko ; OGAWA, Seishi ; IMATAKI, Osamu ; CHIBA, Shigeru</creator><creatorcontrib>HORI, Akiko ; KANDA, Yoshinobu ; KOJIMA, Rie ; HAMAKI, Tamae ; SAKIYAMA, Michiyo ; KAMI, Masahiro ; MAKIMOTO, Atsushi ; TANOSAKI, Ryuji ; TAKAUE, Yoichi ; HIRAI, Hisamaru ; GOYAMA, Susumu ; ONISHI, Yasushi ; KOMENO, Yukiko ; MITANI, Kinuko ; KISHI, Yukiko ; OGAWA, Seishi ; IMATAKI, Osamu ; CHIBA, Shigeru ; Japan Hematology and Oncology Clinical Study Group</creatorcontrib><description>This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum dose was administered over 8 weeks. There were no severe adverse events caused by pravastatin. A clinical response was observed in the skin score in two patients, mouth score in five patients, eye score in two patients, liver score in three patients, platelet count score in one patient, and weight loss in two patients. The overall response rate was 28%. Immunophenotypic analyses showed that T-helper (Th)1 cells were dominant in all but one patient before treatment and that the Th1/Th2 ratio tended to be lower in the responders than in the nonresponders. A randomized controlled trial is warranted to evaluate the efficacy of pravastatin against chronic GVHD.</description><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/01.tp.0000151001.64189.1d</identifier><identifier>PMID: 15699774</identifier><identifier>CODEN: TRPLAU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Biological and medical sciences ; Chronic Disease ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Graft vs Host Disease - drug therapy ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Medical sciences ; Pravastatin - adverse effects ; Pravastatin - therapeutic use ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Th1 Cells - drug effects ; Th1 Cells - immunology ; Th2 Cells - drug effects ; Th2 Cells - immunology ; Tissue, organ and graft immunology</subject><ispartof>Transplantation, 2005-02, Vol.79 (3), p.372-374</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c522t-adb72671d9796ad7a9d5072b40079846201054a317e6d58cf45027060e4e2be23</citedby><cites>FETCH-LOGICAL-c522t-adb72671d9796ad7a9d5072b40079846201054a317e6d58cf45027060e4e2be23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16527744$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15699774$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HORI, Akiko</creatorcontrib><creatorcontrib>KANDA, Yoshinobu</creatorcontrib><creatorcontrib>KOJIMA, Rie</creatorcontrib><creatorcontrib>HAMAKI, Tamae</creatorcontrib><creatorcontrib>SAKIYAMA, Michiyo</creatorcontrib><creatorcontrib>KAMI, Masahiro</creatorcontrib><creatorcontrib>MAKIMOTO, Atsushi</creatorcontrib><creatorcontrib>TANOSAKI, Ryuji</creatorcontrib><creatorcontrib>TAKAUE, Yoichi</creatorcontrib><creatorcontrib>HIRAI, Hisamaru</creatorcontrib><creatorcontrib>GOYAMA, Susumu</creatorcontrib><creatorcontrib>ONISHI, Yasushi</creatorcontrib><creatorcontrib>KOMENO, Yukiko</creatorcontrib><creatorcontrib>MITANI, Kinuko</creatorcontrib><creatorcontrib>KISHI, Yukiko</creatorcontrib><creatorcontrib>OGAWA, Seishi</creatorcontrib><creatorcontrib>IMATAKI, Osamu</creatorcontrib><creatorcontrib>CHIBA, Shigeru</creatorcontrib><creatorcontrib>Japan Hematology and Oncology Clinical Study Group</creatorcontrib><title>A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease</title><title>Transplantation</title><addtitle>Transplantation</addtitle><description>This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum dose was administered over 8 weeks. There were no severe adverse events caused by pravastatin. A clinical response was observed in the skin score in two patients, mouth score in five patients, eye score in two patients, liver score in three patients, platelet count score in one patient, and weight loss in two patients. The overall response rate was 28%. Immunophenotypic analyses showed that T-helper (Th)1 cells were dominant in all but one patient before treatment and that the Th1/Th2 ratio tended to be lower in the responders than in the nonresponders. A randomized controlled trial is warranted to evaluate the efficacy of pravastatin against chronic GVHD.</description><subject>Biological and medical sciences</subject><subject>Chronic Disease</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Graft vs Host Disease - drug therapy</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Medical sciences</subject><subject>Pravastatin - adverse effects</subject><subject>Pravastatin - therapeutic use</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Th1 Cells - drug effects</subject><subject>Th1 Cells - immunology</subject><subject>Th2 Cells - drug effects</subject><subject>Th2 Cells - immunology</subject><subject>Tissue, organ and graft immunology</subject><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkc2O1DAQhC0EYoeFV0DmALeEbseO4-Nq-ZVWgsNytnqcDhOUSQbbGWnegMfGuzvS9MEtWV_Zqioh3iHUCM5-BKzzoYYyaLAcdauxczX2z8QGTaOrFjp4LjYAGitsGnslXqX0p_CmsfaluELTOmet3oh_N_IQl3TgkMcjyxxHmmReJB9pWimXmx3LRAPnk6S5lzwMY6BwkstQhHSklCmPsxyW-IjmyJT3POcHIPIQKeQlnmTYxWUeg_wdacjVkWNaU7VbUpb9mJgSvxYvBpoSvznva_Hry-f722_V3Y-v329v7qpglMoV9VurWou9s66l3pLrDVi11QDWdbpVgGA0NWi57U0XBm1AWWiBNastq-ZafHh6t9j-u3LKfj-mwNNEMy9r8uhUBwp1Ad0TGEo-qVjxhzjuKZ48gn-owQP6-5_-UoN_rMHjp6J9e_5k3e65vyjPuRfg_RmgFGgqMc1hTBeuNapguvkPjL6Svw</recordid><startdate>20050215</startdate><enddate>20050215</enddate><creator>HORI, Akiko</creator><creator>KANDA, Yoshinobu</creator><creator>KOJIMA, Rie</creator><creator>HAMAKI, Tamae</creator><creator>SAKIYAMA, Michiyo</creator><creator>KAMI, Masahiro</creator><creator>MAKIMOTO, Atsushi</creator><creator>TANOSAKI, Ryuji</creator><creator>TAKAUE, Yoichi</creator><creator>HIRAI, Hisamaru</creator><creator>GOYAMA, Susumu</creator><creator>ONISHI, Yasushi</creator><creator>KOMENO, Yukiko</creator><creator>MITANI, Kinuko</creator><creator>KISHI, Yukiko</creator><creator>OGAWA, Seishi</creator><creator>IMATAKI, Osamu</creator><creator>CHIBA, Shigeru</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20050215</creationdate><title>A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease</title><author>HORI, Akiko ; KANDA, Yoshinobu ; KOJIMA, Rie ; HAMAKI, Tamae ; SAKIYAMA, Michiyo ; KAMI, Masahiro ; MAKIMOTO, Atsushi ; TANOSAKI, Ryuji ; TAKAUE, Yoichi ; HIRAI, Hisamaru ; GOYAMA, Susumu ; ONISHI, Yasushi ; KOMENO, Yukiko ; MITANI, Kinuko ; KISHI, Yukiko ; OGAWA, Seishi ; IMATAKI, Osamu ; CHIBA, Shigeru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c522t-adb72671d9796ad7a9d5072b40079846201054a317e6d58cf45027060e4e2be23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Biological and medical sciences</topic><topic>Chronic Disease</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Graft vs Host Disease - drug therapy</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Medical sciences</topic><topic>Pravastatin - adverse effects</topic><topic>Pravastatin - therapeutic use</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Th1 Cells - drug effects</topic><topic>Th1 Cells - immunology</topic><topic>Th2 Cells - drug effects</topic><topic>Th2 Cells - immunology</topic><topic>Tissue, organ and graft immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HORI, Akiko</creatorcontrib><creatorcontrib>KANDA, Yoshinobu</creatorcontrib><creatorcontrib>KOJIMA, Rie</creatorcontrib><creatorcontrib>HAMAKI, Tamae</creatorcontrib><creatorcontrib>SAKIYAMA, Michiyo</creatorcontrib><creatorcontrib>KAMI, Masahiro</creatorcontrib><creatorcontrib>MAKIMOTO, Atsushi</creatorcontrib><creatorcontrib>TANOSAKI, Ryuji</creatorcontrib><creatorcontrib>TAKAUE, Yoichi</creatorcontrib><creatorcontrib>HIRAI, Hisamaru</creatorcontrib><creatorcontrib>GOYAMA, Susumu</creatorcontrib><creatorcontrib>ONISHI, Yasushi</creatorcontrib><creatorcontrib>KOMENO, Yukiko</creatorcontrib><creatorcontrib>MITANI, Kinuko</creatorcontrib><creatorcontrib>KISHI, Yukiko</creatorcontrib><creatorcontrib>OGAWA, Seishi</creatorcontrib><creatorcontrib>IMATAKI, Osamu</creatorcontrib><creatorcontrib>CHIBA, Shigeru</creatorcontrib><creatorcontrib>Japan Hematology and Oncology Clinical Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HORI, Akiko</au><au>KANDA, Yoshinobu</au><au>KOJIMA, Rie</au><au>HAMAKI, Tamae</au><au>SAKIYAMA, Michiyo</au><au>KAMI, Masahiro</au><au>MAKIMOTO, Atsushi</au><au>TANOSAKI, Ryuji</au><au>TAKAUE, Yoichi</au><au>HIRAI, Hisamaru</au><au>GOYAMA, Susumu</au><au>ONISHI, Yasushi</au><au>KOMENO, Yukiko</au><au>MITANI, Kinuko</au><au>KISHI, Yukiko</au><au>OGAWA, Seishi</au><au>IMATAKI, Osamu</au><au>CHIBA, Shigeru</au><aucorp>Japan Hematology and Oncology Clinical Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease</atitle><jtitle>Transplantation</jtitle><addtitle>Transplantation</addtitle><date>2005-02-15</date><risdate>2005</risdate><volume>79</volume><issue>3</issue><spage>372</spage><epage>374</epage><pages>372-374</pages><issn>0041-1337</issn><eissn>1534-6080</eissn><coden>TRPLAU</coden><abstract>This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum dose was administered over 8 weeks. There were no severe adverse events caused by pravastatin. A clinical response was observed in the skin score in two patients, mouth score in five patients, eye score in two patients, liver score in three patients, platelet count score in one patient, and weight loss in two patients. The overall response rate was 28%. Immunophenotypic analyses showed that T-helper (Th)1 cells were dominant in all but one patient before treatment and that the Th1/Th2 ratio tended to be lower in the responders than in the nonresponders. A randomized controlled trial is warranted to evaluate the efficacy of pravastatin against chronic GVHD.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>15699774</pmid><doi>10.1097/01.tp.0000151001.64189.1d</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0041-1337
ispartof Transplantation, 2005-02, Vol.79 (3), p.372-374
issn 0041-1337
1534-6080
language eng
recordid cdi_proquest_miscellaneous_19280214
source MEDLINE; Journals@Ovid Complete
subjects Biological and medical sciences
Chronic Disease
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Graft vs Host Disease - drug therapy
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Medical sciences
Pravastatin - adverse effects
Pravastatin - therapeutic use
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Th1 Cells - drug effects
Th1 Cells - immunology
Th2 Cells - drug effects
Th2 Cells - immunology
Tissue, organ and graft immunology
title A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T03%3A24%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prospective%20trial%20to%20evaluate%20the%20safety%20and%20efficacy%20of%20pravastatin%20for%20the%20treatment%20of%20refractory%20chronic%20graft-versus-host%20disease&rft.jtitle=Transplantation&rft.au=HORI,%20Akiko&rft.aucorp=Japan%20Hematology%20and%20Oncology%20Clinical%20Study%20Group&rft.date=2005-02-15&rft.volume=79&rft.issue=3&rft.spage=372&rft.epage=374&rft.pages=372-374&rft.issn=0041-1337&rft.eissn=1534-6080&rft.coden=TRPLAU&rft_id=info:doi/10.1097/01.tp.0000151001.64189.1d&rft_dat=%3Cproquest_cross%3E19280214%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19280214&rft_id=info:pmid/15699774&rfr_iscdi=true